Ozempic Gastroparesis Attorney: Understanding Florida's Statute of Limitations

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Pharmaceutical Risk Awareness

For decades, public health communication has centered on general wellness and the science of common metabolic conditions, providing broad guidance on diet, exercise, and disease prevention. This foundational approach has served to educate diverse populations about maintaining health and recognizing early warning signs of systemic disorders. Within this legacy framework, the focus remained on lifestyle factors and routine medical management, without delving into the specific risks associated with particular pharmaceutical interventions or their long-term consequences. As medical science advances, the scope of health information must expand to address emerging concerns linked to widely prescribed treatments. One such area involves the growing use of glucagon-like peptide-1 receptor agonists, originally developed for metabolic regulation, and the subsequent recognition of potential gastrointestinal complications. In particular, reports of delayed gastric emptying—a condition that can significantly impair quality of life—have prompted closer examination of the relationship between these medications and digestive system function. This transition from general health education to a more targeted inquiry requires careful attention to the legal and clinical dimensions of exposure. For individuals who have experienced adverse effects following use of these therapies, understanding the applicable legal timeframes becomes critical. In Florida, the statute of limitations for filing claims related to such injuries imposes strict deadlines, underscoring the need for timely consultation with legal professionals specializing in pharmaceutical liability.

The Link Between Ozempic and Gastroparesis: Clinical Evidence

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus. Its pharmacological action includes slowing gastric emptying, which is a known mechanism that can contribute to gastrointestinal adverse effects. Gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. Clinical trial data for Ozempic demonstrate a significantly higher incidence of gastrointestinal adverse reactions compared to placebo. In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those receiving Ozempic 0.5 mg, and 36.4% of those receiving Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate that Ozempic use is associated with a range of upper gastrointestinal symptoms that overlap with the clinical presentation of gastroparesis.

Mechanistic Pathway and Warning Gaps

The mechanistic pathway linking Ozempic to gastroparesis involves the drug's effect on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to prolonged retention of gastric contents. This pharmacodynamic effect is dose-dependent and can persist with continued use. While the drug's labeling acknowledges gastrointestinal adverse reactions, it does not specifically warn about the risk of developing gastroparesis as a distinct clinical condition. The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration for affected patients. The prescribing information lists nausea, vomiting, diarrhea, abdominal pain, and constipation as common adverse reactions but does not explicitly mention gastroparesis or provide guidance on monitoring for delayed gastric emptying (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This gap may affect patients who develop persistent symptoms consistent with gastroparesis after starting Ozempic.

Florida Statute of Limitations for Ozempic-Related Claims

For patients in Florida who have developed gastroparesis potentially linked to Ozempic use, attorney-related considerations include the statute of limitations for filing a product liability claim. In Florida, the statute of limitations for personal injury claims is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the limit is two years. The timeline between exposure to Ozempic and documented harm is critical for establishing causation and meeting legal deadlines. Patients should document the start date of Ozempic use, the onset of gastrointestinal symptoms, and any medical diagnoses of gastroparesis. Medical records, including gastric emptying studies and physician notes linking symptoms to the medication, are essential evidence.

Risk Narrative and Temporal Relationship

The risk narrative for Ozempic-associated gastroparesis involves a clear temporal relationship: gastrointestinal adverse reactions are most common during dose escalation, but symptoms can persist or worsen over time. The drug's labeling indicates that nausea, vomiting, and diarrhea occur more frequently in Ozempic-treated patients than placebo, with higher rates at higher doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Patients who experience severe or prolonged symptoms should seek medical evaluation for gastroparesis. The mechanistic plausibility, combined with clinical trial data showing dose-dependent gastrointestinal effects, supports a potential link between Ozempic and gastroparesis.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for an Ozempic gastroparesis claim in Florida?

In Florida, the statute of limitations for personal injury claims, including product liability related to Ozempic, is generally four years from the date the injury was discovered or should have been discovered with reasonable diligence. For wrongful death claims, the limit is two years. It is crucial to consult an attorney promptly to ensure your claim is filed within the applicable deadline.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying by inhibiting antral contractions and stimulating pyloric tone. This pharmacodynamic effect can lead to prolonged retention of gastric contents, resulting in symptoms consistent with gastroparesis. Clinical trial data show a significantly higher incidence of gastrointestinal adverse reactions in Ozempic-treated patients compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.